Polypeptide svD2 Adaptive Immune Activation for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and viral infections often target human processes, leading to toxic side effects and are susceptible to resistance, while the immune system's ability to combat pathogens is weakened, allowing cancer cells to evade immune defenses.
Innovation Solution
Administration of a polypeptide with the amino acid sequence VSNQH or its branched forms, which stimulates the adaptive immune system by increasing cytokine release, particularly IL-21, to enhance B cell and B memory cell development, activation, and maturation, thereby boosting the immune response against cancer and infectious agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (chemotherapy, antibiotics) are used to target cancer cells and pathogens, then direct therapeutic effect is achieved, but toxic side effects and resistance develop
Solution Approach 1:
The patent introduces a polypeptide as an intermediary substance that activates the patient's own immune system (B cells, T cells, NK cells) to attack cancer cells. Instead of directly targeting cancer with toxic agents, the polypeptide mediates immune activation, allowing the body's natural defenses to eliminate tumors without the severe toxicity of conventional chemotherapy.
2Adaptability or versatility
If the immune system is activated to combat cancer, then broad spectrum defense capacity is improved, but the immune system may be weakened by stress, illness, malnutrition, or age
Solution Approach 1:
The polypeptide is administered before cancer progression or immune collapse occurs, serving as a preventive immune booster. By activating immune cells in advance through IL-21 induction, the treatment prepares the immune system to effectively combat cancer cells before they establish significant tumors or before immune function deteriorates due to stress, age, or illness.
3Reliability
If cancer cells are allowed to evade immune defenses, then tumor growth occurs, but the immune system's natural defense mechanisms are insufficient without activation
Solution Approach 1:
The polypeptide fundamentally changes the functional state of immune cells by inducing IL-21 production and activating transcription factors like NF-κB and AP-1. This parameter change transforms quiescent or suppressed immune cells into highly active anti-tumor effectors, enabling them to recognize and destroy cancer cells that would otherwise evade detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively stimulates the immune system, increasing the density of cellular markers on peritoneal cells, inducing the production of cytokines beneficial for cancer cell destruction, and improving survival rates in subjects with tumors by enhancing the body's natural defense mechanisms without causing toxic side effects.
Implementation Method 1
a polypeptide that induces a greater release of the cytokine IL-21 in a cytokine release assay than IFNγ
Implementation Method 2
Administration of a polypeptide with the amino acid sequence VSNQH or its branched forms, which stimulates the adaptive immune system by increasing cytokine release
Data Source
AI summary
Polypeptides, such as a multi-valent polypeptide designated svD2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. svD2 demonstrated in vivo activity in a syngeneic mouse model. svD2 is biologically active at nanomolar concentrations. These properties are believed to result as a consequence of the ability of svD2 to cross-link cell-surface receptors.